JNJ
Another day, another talc headache
Johnson & Johnson is back in court trouble, and this one comes with a very familiar sting: a Los Angeles jury awarded $32 million to the family of Maria Lozano, who died in 2024 from pleural mesothelioma after years of alleged exposure to an asbestos-contaminated talc product.
The jury found J&J and its subsidiaries liable, which means this isn’t just noise—it’s the kind of verdict that keeps legal overhangs hanging around like a song you can’t get out of your head.
Why investors should care
For shareholders, the headline risk here isn’t just the dollar amount. It’s the reminder that J&J’s talc litigation machine is still very much running, and every new verdict can add pressure on settlement talks, reserves, and sentiment.
- The case involved a California family continuing the lawsuit after Lozano’s death.
- The verdict adds to J&J’s broader asbestos/talc legal baggage.
- Even when verdicts get appealed or reduced, they can still keep the stock in “legal uncertainty” mode.
Big picture
J&J is still a giant, still diversified, and still plenty capable of shrugging off single-case drama. But if you own the stock, you don’t get to pretend the talc issue is gone just because the market has better things to obsess over. The courtroom drumbeat is still there, and so is the risk that it keeps getting louder.